克洛-米R-14:一种具有医学价值的香料衍生的miRNA,在类风湿性关节炎中具有治疗意义
Ashish Sarkar1,2, Mohd Saquib1,2, Debolina Chakraborty1,2
1Council of Scientific & Industrial Research (CSIR)-Institute of Genomics and Integrative Biology, Delhi University Campus, Mall Road, Delhi, 110007, India.
Bioscience reports
|August 28, 2024
概括
食植物微RNAs (miRNAs) 显示出作为基于RNA的药物的潜力. 长 (Curcuma longa) 是一种长.
科学领域:
- 植物分子生物学 植物分子生物学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 植物微RNAs (miRNAs) 是口服的,可以调节哺乳动物的基因表达.
- 药用植物具有抗炎性质,但它们的miRNA贡献未得到充分研究.
- 类风湿性关节炎 (RA) 是一种慢性炎症疾病,治疗选择有限.
研究的目的:
- 研究植物衍生的miRNAs在治疗类风湿性关节炎 (RA) 中的治疗潜力.
- 为验证Curcuma longa中的Clo-miR-14在RA患者中的稳定性和吸收性.
- 评估Clo-miR-14在改善RA类症状中的疗效,在体外和体内.
主要方法:
- 从四种医学上有价值的香料中选miRNAs.
- 使用RT-PCR验证Clo-miR-14的热稳定性和血吸收.
- 在体外和体内研究,以评估Clo-miR-14对RA病变发生的作用.
主要成果:
- 来自Curcuma longa的Clo-miR-14在100°C时表现出强大的热稳定性.
- 克洛-米R-14被吸收到RA患者的血样本中.
- 观察到促炎性细胞因子 (TNF,IL-1β,IL-6) 和RA类症状的显著减少.
结论:
- 外源植物基miRNA,Clo-miR-14,是热稳定和口服生物可用.
- 克洛-米R-14通过减少关键的炎症标志物,有效地改善了类似RA的症状.
- 来自植物的miRNAs代表了基于RNA的新型RA治疗方法的有希望的途径.
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
145
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
145
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
120
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
120
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
98
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
98
01:24T Cell Types and Functions
963
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
963
01:29Inflammatory Bowel Disease IV: Pharmacological Management
123
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
123
01:20The JAK-STAT Signaling Pathway
8.7K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.7K